Plus Therapeutics Provides Updates on ReSPECT Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (GlobeNewswire) - Nov 19, 2022 - P1/2a | N=55 | ReSPECT (NCT01906385) | Sponsor: Plus Therapeutics | "The oral presentation...included the following key findings: In 24 patients with recurrent glioblastoma, a single dose of rhenium (186Re) obisbemeda was administered in the dose escalation phase, (range: 1.0 mCi/0.66 mL to 31.2 mCi/12.3 mL), achieving up to 740 Gray (Gy) of absorbed radiation dose to the tumor....A statistically significant improvement in overall survival correlated with both the average absorbed dose of radiation to the tumor and the percent volume of tumor treated, specifically: A 100 Gy increase in the absorbed dose correlated with a 35.7% decrease in the risk of death (p=0.003, Cox methods hazard ratios = 0.643); A 1% increase in tumor volume treated is associated with a 4.5% decrease in the risk of death (p=0.002, Cox methods hazard ratios = 0.955)."
P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
|